Dr. Xingli Wang

You really don't know until you test it.

So we sometimes also, you know, while we try all different solid tumors, this is one of the reasons.

I think we have a very high hope on this drug to make, you know, to become a blockbuster.

For the next three to five years, this will become a regular, normal practice.

It's not only the model, it's not only we have our early asset, good asset by license out.

We call license out as general term, but more or less as a co-development.

We're also working on with some of the US very big capital fund of the order to make type of collaboration.

They nominate target we produce.

There's another way as reverse type of collaboration.

We use the strength of our efficiency productivity

They use their knowledge.

Again, this is not going to be a kind of like overwhelming strategy.

This is going to be like somewhat transient strategy of one, you get some access to the global or international fund.

Two, you get access to global talents.

And they do, you know, we must admit our team drug development competence or the ability is not as good up to par with our international colleagues.

And three, the market understanding.

As you know, the health care is often local for local, even though we have a global guidelines.

But still, the local practices are different when it comes to clinical trials of MRCTs.

That has to be part of your major design.

When I was running global trials in the Emirates, one of the main learnings is some of the country-to-country differences in clinical practice, which can often affect your clinical trial outcome.